OmniAb Results Presentation Deck

Q2 2023 and Recent Updates SELECT RECENT DEVELOPMENTS SHOW CONTINUED PARTNER MOMENTUM FcRn Batoclimab HARBOUR BIOMED 1 HANALL>< BIOPHARMA IMMUNOVANT Immunovant is conducting advanced-stage studies in: generalized Myasthenia Gravis (gMG) (P3) Thyroid Eye Disease (P3) Chronic Inflammatory Demyelinating Polyneuropathy (P2b) Graves' Disease (P2) Harbour BioMed announced BLA acceptance of batoclimab for treatment of gMG in China HanAll announced progression towards initiation of a Phase 3 clinical study of batoclimab in gMG in Japan in 2023 FcRn ● IMVT-1402 Reference: Partner and Company disclosures HANALLX IMMUNOVANT BIOPHARMA Immunovant initiated a Phase 1 clinical trial of IMVT-1402 in healthy volunteers; expects Phase 1 data in second half of 2023 CSX-1004 Anti-fentanyl (and related synthetic opioids) ● CESSATION THERAPEUTICS Cessation Therapeutics announced FDA authorization for First-in- Human clinical trial CSX-1004 is being developed for prevention of fentanyl overdose, which claimed more than 74,000 American lives last year Cessation expects to initiate trial in August APVO436 CD123 x CD3 Aptevo Therapeutics Aptevo Therapeutics announced that APVO436, in combination with venetoclax and azacitidine, achieved positive duration of remission results in its Phase 1B dose-escalation trial Aptevo intends to conduct two Phase 2 clinical trials to include relapsed/refractory AML patients beginning in the second half of 2023 and frontline patients beginning in the first half of 2024 GSK Program-1 Ion Channels and Transporters 10 GSK OmniAb, Inc. achieved a $2 million research progression milestone in Q2 for small molecule inhibitors of a genetically- validated target relevant to neurological diseases OmniAb

View entire presentation